Contrasting Dominari (NASDAQ:DOMH) and Associated Capital Group (NYSE:AC)

Dominari (NASDAQ:DOMH) and Associated Capital Group (NYSE:AC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, dividends, earnings, valuation and risk.

Risk & Volatility

Dominari has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500. Comparatively, Associated Capital Group has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500.

Profitability

This table compares Dominari and Associated Capital Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Dominari	N/A	-37.80%	-34.85%
Associated Capital Group	295.29%	4.15%	4.00%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Dominari and Associated Capital Group, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dominari	0	0	0	0	N/A
Associated Capital Group	0	1	5	0	2.83

Associated Capital Group has a consensus price target of $27.50, indicating a potential downside of 14.46%. Given Associated Capital Group’s higher possible upside, analysts plainly believe Associated Capital Group is more favorable than Dominari.

Valuation & Earnings

This table compares Dominari and Associated Capital Group’s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dominari	$2.04 million	6.74	-$22.88 million	($4.44)	-0.52
Associated Capital Group	$12.68 million	54.49	$37.45 million	$1.72	18.69

Associated Capital Group has higher revenue and earnings than Dominari. Dominari is trading at a lower price-to-earnings ratio than Associated Capital Group, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

42.5% of Dominari shares are owned by institutional investors. Comparatively, 8.1% of Associated Capital Group shares are owned by institutional investors. 9.7% of Dominari shares are owned by insiders. Comparatively, 85.6% of Associated Capital Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Associated Capital Group beats Dominari on 11 of the 13 factors compared between the two stocks.

About Dominari

Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.

About Associated Capital Group

Associated Capital Group, Inc., together with its subsidiaries, provides investment advisory services in the United States. The company offers alternative investment management services; and operates a direct investment business. It also invests in new and existing businesses. The company was founded in 1976 and is headquartered in Greenwich, Connecticut. Associated Capital Group, Inc. operates as a subsidiary of GGCP Holdings LLC.